Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920296 · ClinicalTrials.gov registry record · Phase 1
DDI Study of Etravirine and GSK1265744
A Phase 1 study of Healthy Subjects and Infection, Human Immunodeficiency Virus, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00920296: Completed Phase 1 study of Healthy Subjects and Infection, Human Immunodeficiency Virus, sponsored by GlaxoSmithKline.
NCT00920296 is a Phase 1 study of Healthy Subjects and Infection, Human Immunodeficiency Virus that has completed, run by GlaxoSmithKline. The registered enrollment target is 12 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920296, a Phase 1 study of Healthy Subjects and Infection, Human Immunodeficiency Virus, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
Conditions Studied
Interventions
- DRUG GSK1265744
Study Locations (1)
Texas
- GSK Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00920296 record still lists
NCT00920296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which GSK1265744 is the first listed.
NCT00920296 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00920296 about?
NCT00920296 is a clinical study titled "DDI Study of Etravirine and GSK1265744". The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
What is the current status of trial NCT00920296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-07. Estimated completion is 2009-09.
What conditions does trial NCT00920296 study?
This clinical trial studies the following conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT00920296?
The interventions under investigation include: GSK1265744 (DRUG).
Who is sponsoring clinical trial NCT00920296?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920296 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00920296's enrollment target sits among peer trials
12 62nd of 69 higher than 6 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia